MEDIROM Announces Receipt of Nasdaq Delisting Notice, Filing of Annual Report and Submission of Hearing Request
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
MEDIROM Healthcare Technologies (Nasdaq: MRM) received a Nasdaq delisting notice on November 13, 2026, after missing its extended deadline to file its annual report. It filed its Form 20-F for the year ended December 31, 2025, with the SEC on November 18 and requested a Nasdaq hearing that day. The request automatically pauses any trading suspension for 15 days from the request date. MEDIROM requested a longer pause while the appeal is heard, but continued listing remains unresolved.
The filing does not resolve the separate minimum bid price deficiency. MEDIROM has until April 5, 2027, to regain bid price compliance.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate pointAnnual report filed with the SEC on November 18, 2026, and presented to Nasdaq in support of the appeal
- Minor pointTimely hearing request automatically stays any suspension of American Depositary Share trading for 15 days from the request date
Negative
- Major pointNasdaq delisting notice followed MEDIROM’s failure to file its annual report within the extension period
- Moderate pointSeparate minimum bid price deficiency remains unresolved, with a compliance deadline of April 5, 2027
- Minor pointContinued listing remains unresolved despite the annual report filing
- Minor point. Forward-looking: it has not happened yet and may not happen.Trading suspension stay beyond 15 days has been requested but is not assured
Key Figures
- Stated suspension and delisting date
- November 24, 2026
- The Notice stated this would apply unless the Company requested an appeal
- Hearing request date
- November 18, 2026
- The Company submitted a request to appeal the delisting determination
- Automatic stay period
- 15 days
- From the date of the hearing request
- Annual Report filing date
- November 18, 2026
- Filed with the U.S. Securities and Exchange Commission
- Minimum bid-price compliance deadline
- April 5, 2027
- Separate deficiency under Nasdaq Listing Rule 5550(a)(2)
Key Terms
form 20-f regulatory
nasdaq listing rule 5250(c)(1) regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
TOKYO, Nov. 18, 2026 (GLOBE NEWSWIRE) -- MEDIROM Healthcare Technologies Inc. (Nasdaq: MRM) (the “Company”) today announced that on November 13, 2026, it received a notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) because the Company had not filed its Annual Report on Form 20-F for the year ended December 31, 2025 (the “Annual Report”) within the extension period previously granted by Nasdaq and therefore had not regained compliance with Nasdaq Listing Rule 5250(c)(1).
As previously disclosed, Nasdaq notified the Company on May 26, 2026, that it was not in compliance with Nasdaq Listing Rule 5250(c)(1) because it had not timely filed the Annual Report. Nasdaq subsequently granted the Company an extension to regain compliance. The Company did not file the Annual Report within that extension period. The Notice stated that unless the Company requests an appeal of the delisting determination, trading of the Company’s American Depositary Shares will be subject to suspension and delisting from Nasdaq at the opening of business on November 24, 2026.
On November 18, 2026, the Company timely submitted a request for a hearing before a Nasdaq Hearings Panel (the “Panel”) to appeal the determination. Under the applicable Nasdaq rules, the hearing request automatically stays any suspension of trading in the Company’s American Depositary Shares (“ADSs”) for 15 days from the date of the request. The Notice also stated that when the Company requests a hearing, it may also request a stay of the suspension pending the hearing. The Company has requested an extended stay of any trading suspension pending completion of the hearing process.
The Company filed the Annual Report with the U.S. Securities and Exchange Commission on November 18, 2026. The Company has presented the filing of the Annual Report to Nasdaq in support of its appeal and request for continued listing. There can be no assurance that Nasdaq will determine that the filing resolves the Company’s periodic reporting deficiency or results in the cancelation of a hearing, that the Panel will grant any further stay of suspension or the Company’s request for continued listing, or that the Company will regain or maintain compliance with all applicable Nasdaq continued listing requirements.
The Notice relates to the Company’s periodic reporting deficiency. Separately, as previously disclosed, on October 6, 2026, the Company received a notice that it was not in compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2). Nasdaq provided the Company until April 5, 2027, to regain compliance with that requirement. Filing the Annual Report does not resolve this separate minimum bid price deficiency.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of applicable U.S. securities laws, including statements regarding the Company’s appeal of the determination, any further stay of trading suspension, continued listing of the Company’s ADSs, and the Company’s ability to regain or maintain compliance with Nasdaq’s continued listing requirements. These statements are based on current expectations and are subject to risks and uncertainties that could cause actual results to differ materially, including Nasdaq’s response in light of the filing of the Annual Report, the outcome of any hearing process, the Panel’s exercise of discretion, the Company’s ability to satisfy applicable listing requirements, and the other risks described in the Company’s Annual Report on Form 20-F for the year ended December 31, 2025 and its other filings with the U.S. Securities and Exchange Commission. Forward-looking statements speak only as of the date of this release. Except as required by law, the Company undertakes no obligation to update these statements.
About MEDIROM Group
MEDIROM Group operates approximately 281 wellness salons under the “Re.Ra.Ku®” brand nationwide. Since 2015, we have expanded into HealthTech, offering on-demand training apps like Lav® for specific health guidance and lifestyle improvement programs. In 2020, we started manufacturing the 24/7 recharge-free smart tracker “MOTHER Bracelet®,” which is now used in REMONY, our remote monitoring system for various industries including caregiving, transportation, construction, and manufacturing.
About MEDIROM Healthcare Technologies Inc.
NASDAQ Symbol: MRM
Tradepia Odaiba, 2-3-1 Daiba, Minato-ku, Tokyo, Japan
Website: https://medirom.co.jp/en
Contact: ir@medirom.co.jp
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.